FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * GOLDSTEIN ALLAN L 2. Issuer Name and Ticker or Trading Symbol REGENERX BIOPHARMACEUTICALS INC [ RGRX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O REGENERX BIOPHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 470		 3. Date of Earliest Transaction (MM/DD/YYYY)
10/15/2020
(Street)
ROCKVILLE, MD 20850
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 1712793  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $0.21                   (1) 3/25/2021  Common Stock  450000    450000  D   
Stock Option (right to buy)  $0.36                   (1) 6/30/2022  Common Stock  250000    250000  D   
Stock Option (right to buy)  $0.64                   (1) 3/16/2023  Common Stock  200000    200000  D   
Stock Option (right to buy)  $0.28                   (1) 9/1/2027  Common Stock  150000    150000  D   
Stock Option (right to buy)  $0.21                   (2) 7/17/2028  Common Stock  250000    250000  D   
Stock Option (right to buy)  $0.21                   (3) 5/15/2029  Common Stock  410000    410000  D   
Stock Option (right to buy)  $0.30                   (4) 6/10/2030  Common Stock  400000    400000  D   
Convertible Promissory Note (right to buy)  $0.12                  2/27/2019  2/27/2024  Common Stock  20833    $2500.00  D   
Convertible Promissory Note (right to buy)  $0.12                  5/13/2019  5/13/2024  Common Stock  20833    $2500.00  D   
Common Stock Warrant (right to buy)  $0.18                  8/27/2019  2/27/2024  Common Stock  15625    15625  D   
Common Stock Warrant (right to buy)  $0.18                  11/13/2019  5/13/2024  Common Stock  15625    15625  D   
Convertible Promissory Note (right to buy)  $0.36  10/15/2020    P     $5000      10/15/2020  10/15/2025  Common Stock  13920  $5000  $5000  D   
Common Stock Warrant (right to buy)  $0.45  10/15/2020    P     10440      4/15/2021  10/15/2025  Common Stock  10440  $0  10440  D   

Explanation of Responses:
(1)  100% vested.
(2)  62,500 shares vest on each of 7/17/18, 7/17/19, 7/17/20 and 7/17/21.
(3)  102,500 shares vest on each of 5/15/19, 5/15/20, 5/15/21 and 5/15/22.
(4)  100,000 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GOLDSTEIN ALLAN L
C/O REGENERX BIOPHARMACEUTICALS, INC.
15245 SHADY GROVE ROAD, SUITE 470
ROCKVILLE, MD 20850		 X



Signatures
/s/ Andrew Nick as Attorney-in-Fact for Allan Goldstein, Ph.D. pursuant to Power of Attorney previously filed. 10/20/2020
**Signature of Reporting Person Date